Cardiology Research and Practice / 2018 / Article / Tab 1

Research Article

Extended Use of the Wearable Cardioverter-Defibrillator: Which Patients Are Most Likely to Benefit?

Table 1

Studies reviewed.

YearAuthorIndicationMedian wear timeMaximal wear timeNumber of appropriate shocksMedian time to the first appropriate shockMaximal time to the first appropriate shock

2010Collins et al. [14]Any (≤18 years of age)81295310No shocksNo shocks
Any (18–21 years of age)103354995
2010Chung et al. [15]Any356936159080
2010Klein et al. [24]Any354106a>7 years21
2010Dillon et al. [17]Any21053636554
2012Kao et al. [23]Heart failureb82642770No shocksNo shocks
2013Epstein et al. [22]ICM8453573099>9 months
2014Wan et al. [21]Hemodialysed patientsc7562.9a308136
2014Tanawuttiwat et al. [20]Device infection9721d42338
2015Singh et al. [19]ICM2715363445
NICM254710No shocksNo shocks
2016Lamichhane et al. [18]HFrEFe220394201313
2016Wäßnig et al. [13]Any604359163f
2017Erath et al. [25]Any1102541668
2017Sasaki et al. [26]Any501617161230
2017Duncker et al. [16]PPCM49120a568124g

aReported as a mean; bdefined by own specific criteria; conly patients with SCD events included; dmedian calculated for only 80 study patients; ewear time always >90 days; f89% of treatments occurred in the first 90 days; gcalculated from the time of diagnosis and not from the beginning of device therapy; not reported. Time is presented in days.

You are browsing a BETA version of Click here to switch back to the original design.